CGRP in Childhood and Adolescence Migraine: (Patho)physiological and Clinical Aspects

Stefan Evers, Stefan Evers

Abstract

Purpose of review: To summarise and analyse the current knowledge of CGRP metabolism in childhood and adolescence and its role in childhood and adolescence migraine.

Recent findings: Influencing CGRP pathways is nowadays one of the main mechanisms to treat migraine. In adults, several clinical trials with different drug classes have supported this finding. However, only very little is known on these mechanisms in children and adolescents with migraine. Based on a literature search, it can be concluded that substantial parts of the CGRP pathways are already developed and working in the preterm fetus of animals. Newborn animals show high CGRP levels and high density of CGRP positive neurons and nerve fibres. In human studies, increased levels of CGRP were observed in childhood and adolescent migraine patients. Remedies based on influencing CGRP metabolism are also working in that age group. For triptans, this has clearly been shown; for gepants, no data are available, and for CGRP ligand/receptor antibodies, positive evidence is only available from case series. Only very little is known on CGRP metabolism in childhood and adolescence. However, placebo-controlled clinical trials both on CGRP antagonists and on CGRP ligand/receptor antibodies are under way and will show in some years whether these drug classes are efficacious also in children and adolescents.

Keywords: Antibodies; Calcitonin gene-related peptide (CGRP); Gepants; Migraine; Triptans.

Conflict of interest statement

The author declares no conflict of interest. This manuscript was not supported by any company or other commercial influences. The author is speaking for and member of advisory boards for the following companies (past three years): Lilly; Lundbeck; Novartis; Perfood; Teva.

© 2022. The Author(s).

References

    1. Dong YL, Vegiraju S, Chauhan M, Yallampalli C. Expression of calcitonin gene-related peptide receptor components, calcitonin receptor-like receptor and receptor activity modifying protein 1, in the rat placenta during pregnancy and their cellular localization. Mol Hum Reprod. 2003;9:481–490. doi: 10.1093/molehr/gag058.
    1. Dong YL, Vegiraju S, Gangula PR, et al. Expression and regulation of calcitonin gene-related peptide receptor in rat placentas. Biol Reprod. 2002;67:1321–1326. doi: 10.1093/biolreprod/67.4.1321.
    1. Parida SK, Schneder DB, Stoss TD, et al. Elevated circulating calcitonin gene-related peptide in umbilical cord and infant blood associated with maternal and neonatal sepsis and shock. Pediatr Res. 1998;43:276–282. doi: 10.1203/00006450-199802000-00020.
    1. Dhall U, Cowen T, Haven AJ, Burnstock G. Perivascular noradrenergic and peptidecontaining nerves show different patterns of changes during development and ageing in the guinea-pig. J Auton Nerv Syst. 1986;16:109–126. doi: 10.1016/0165-1838(86)90003-2.
    1. Connat JL, Busseuil D, Gambert S, Ody M, Tebaldini M, Gamboni S, Faivre B, Quiquerez AL, Millet M, Michaut P, Rochette L. Modification of the rat aortic wall during ageing: possible relation with decrease of peptidergic innervation. Anat Embryol. 2001;204:455–468. doi: 10.1007/s429-001-8002-0.
    1. Gangula PR, Chauhan M, Reed L, Yallampalli C. Age-related changes in dorsal root ganglia, circulating and vascular calcitonin gene-related peptide (CGRP) concentrations in female rats: effect of female sex steroid hormones. Neurosci Lett. 2009;454:118–123. doi: 10.1016/j.neulet.2009.02.068.
    1. Fan PC, Kuo PH, Hu JW, Chang SH, Hsieh ST, Chiou LC. Different trigemino-vascular responsiveness between adolescent and adult rats in a migraine model. Cephalalgia. 2012;32:979–990. doi: 10.1177/0333102412455710.
    1. Quartu M, Diaz G, Floris A, Lai ML, Priestley JV, Del Fiacco M. Calcitonin gene-related peptide in the human trigeminal sensory system at developmental and adult life stages: immunohistochemistry, neuronal morphometry and coexistence with substance P. J Chem Neuroanat. 1992;5:143–157. doi: 10.1016/0891-0618(92)90040-W.
    1. Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol. 1990;28:183–187. doi: 10.1002/ana.410280213.
    1. Cernuda-Morollón E, Larrosa D, Ramón C, Vega J, Martínez-Camblor P, Pascual J. Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine. Neurology. 2013;81:1191–1196. doi: 10.1212/WNL.0b013e3182a6cb72.
    1. Gallai V, Sarchielli P, Floridi A, Franceschini M, Codini M, Glioti G, Trequattrini A, Palumbo R. Vasoactive peptide levels in the plasma of young migraine patients with and without aura assessed both interictally and ictally. Cephalalgia. 1995;15:384–390. doi: 10.1046/j.1468-29821995.1505384.x.
    1. Fan PC, Kuo PH, Chang SH, Lee WT, Wu RM, Chiou LC. Plasma calcitonin gene-related peptide in diagnosing and predicting paediatric migraine. Cephalalgia. 2009;29:883–890. doi: 10.1111/j.1468-2982.2008.01816.x.
    1. Fan PC, Kuo PH, Lee MT, Chang SH, Chiou LC. Plasma calcitonin gene-related peptide: a potential biomarker for diagnosis and therapeutic responses in pediatric migraine. Front Neurol. 2019;10:10. doi: 10.3389/fneur.2019.00010.
    1. Hanci F, Kilinc YB, Kilinc E, Turay S, Dilek M, Kabakus N. Plasma levels of vasoactive neuropeptides in pediatric patients with migraine during attack and attack-free periods. Cephalalgia. 2021;41:166–175. doi: 10.1177/0333102420957588.
    1. Dawidson I, Blom M, Lundeberg T, Theodorsson E, Angmar-Månsson B. Neuropeptides in the saliva of healthy subjects. Life Sci. 1997;60:269–278. doi: 10.1016/S0024-3205(96)00627-3.
    1. Cady R, Turner I, Dexter K, Beach ME, Cady R, Durham P. An exploratory study of salivary calcitonin gene-related peptide levels relative to acute interventions and preventative treatment with onabotulinumtoxinA in chronic migraine. Headache. 2014;54:269–277. doi: 10.1111/head.12250.
    1. Gershan LA, Durham PL, Skidmore J, Shimizu J, Cady RJ, Sheng X, Maloney CG. The role of salivary neuropeptides in pediatrics: potential biomarkers for integrated therapies. Eur J Integr Med. 2015;7:372–377. doi: 10.1016/j.eujim.2015.06.001.
    1. Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol. 1993;33:48–56. doi: 10.1002/ana.410330109.
    1. Hämäläinen ML, Hoppu K, Santavuori P. Sumatriptan for migraine attacks in children: a randomized placebo-controlled study. Do children with migraine respond to oral sumatriptan differently from adults? Neurology 1997;48:1100–1103.
    1. Evers S, Marziniak M, Frese A, Gralow I. Placebo efficacy in childhood and adolescence migraine: an analysis of double-blind and placebo-controlled studies. Cephalalgia. 2009;29:436–444. doi: 10.1111/j.1468-2982.2008.01752.x.
    1. Labastida-Ramirez A, Rubio-Beltran E, Haanes KA, Chan KY, Garrelds IM, Johnson KW, et al. Lasmiditan inhibits calcitonin gene-related peptide release in the rodent trigeminovascular system. Pain. 2020;61:1092–1099. doi: 10.1097/j.pain.0000000000001801.
    1. Tsai M, Nery ESM, Kerr L, Khanna R, Komori M, Dennehy EB, Wilbraham D, Winner P. Pharmacokinetics, safety, and tolerability of lasmiditan in pediatric patients with migraine. Clin Pharmacokinet. 2021;60:819–828. doi: 10.1007/s40262-020-00966-z.
    1. •• Cohen-Barak O, Radivojevic A, Jones A, Fiedler-Kelly J, Gillespie M, Brennan M, Gutman D, Rasamoelisolo M, Hallak H, Loupe P, Kessler Y, Ning X, Levi M, Ahn AH, Rabinovich-Guilatt L. Dose selection for fremanezumab (AJOVY) phase 3 pediatric migraine studies using pharmacokinetic data from a pediatric phase 1 study and a population pharmacokinetic modeling and simulation approach. Cephalalgia 2021;41: 1065–1074. Largest case series on the use of CGRP ligand/receptor antibodies in children and adolescents.
    1. Greene KA, Gentile CP, Szperka CL, Yonker M, Gelfand AA, Grimes B, Irwin SL. Calcitonin gene-related peptide monoclonal antibody use for the preventive treatment of refractory headache disorders in adolescents. Pediatr Neurol. 2021;114:62–67. doi: 10.1016/j.pediatrneurol.2020.09.014.
    1. •• Zhao YJ, Ho KH, Wong PS. Early clinical experience with a monoclonal antibody against the calcitonin gene-related peptide receptor in adolescents with migraine: a case series. Proceedings of Singapore Healthcare 2020;29: 212–214. The only paper with recommendations for the treatment of children and adolescents with CGRP ligan/receptor antibodies.
    1. Szperka CL, VanderPluym J, Orr SL, Oakley CB, Qubty W, Patniyot I, Lagman-Bartolome AM, Morris C, Gautreaux J, Victorio MC, Hagler S, Narula S, Candee MS, Cleves-Bayon C, Rao R, Fryer RH, Bicknese AR, Yonker M, Hershey AD, Powers SW, Goadsby PJ, Gelfand AA. Recommendations on the use of anti-CGRP monoclonal antibodies in children and adolescents. Headache. 2018;58:1658–1669. doi: 10.1111/head.13414.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa